Ai-Wu Ke[Author] - Search Results

Year	Number of Results
2008	4
2009	2
2010	4
2011	6
2012	2
2013	6
2014	9
2015	7
2016	3
2017	4
2018	6
2019	10
2020	6
2021	4
2022	6
2023	7
2024	2

1

Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.

Wang SW, Gao C, Zheng YM, Yi L, Lu JC, Huang XY, Cai JB, Zhang PF, Cui YH, Ke AW. Wang SW, et al. Among authors: ke aw. Mol Cancer. 2022 Feb 21;21(1):57. doi: 10.1186/s12943-022-01518-8. Mol Cancer. 2022. PMID: 35189910 Free PMC article. Review.

2

PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.

Wei CY, Zhu MX, Zhang PF, Huang XY, Wan JK, Yao XZ, Hu ZT, Chai XQ, Peng R, Yang X, Gao C, Gao J, Wang SW, Zheng YM, Tang Z, Gao Q, Zhou J, Fan JB, Ke AW, Fan J. Wei CY, et al. Among authors: ke aw. J Hepatol. 2022 Jul;77(1):163-176. doi: 10.1016/j.jhep.2022.02.019. Epub 2022 Feb 24. J Hepatol. 2022. PMID: 35219791 Free article.

3

Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.

Lu JC, Zhang PF, Huang XY, Guo XJ, Gao C, Zeng HY, Zheng YM, Wang SW, Cai JB, Sun QM, Shi YH, Zhou J, Ke AW, Shi GM, Fan J. Lu JC, et al. Among authors: ke aw. J Hematol Oncol. 2021 Nov 27;14(1):200. doi: 10.1186/s13045-021-01207-x. J Hematol Oncol. 2021. PMID: 34838121 Free PMC article.

4

Macro CD5L⁺ deteriorates CD8⁺T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.

Lu JC, Wu LL, Sun YN, Huang XY, Gao C, Guo XJ, Zeng HY, Qu XD, Chen Y, Wu D, Pei YZ, Meng XL, Zheng YM, Liang C, Zhang PF, Cai JB, Ding ZB, Yang GH, Ren N, Huang C, Wang XY, Gao Q, Sun QM, Shi YH, Qiu SJ, Ke AW, Shi GM, Zhou J, Sun YD, Fan J. Lu JC, et al. Among authors: ke aw. Nat Commun. 2024 Jan 20;15(1):621. doi: 10.1038/s41467-024-44795-1. Nat Commun. 2024. PMID: 38245530 Free PMC article.

5

Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning.

Shi JY, Wang X, Ding GY, Dong Z, Han J, Guan Z, Ma LJ, Zheng Y, Zhang L, Yu GZ, Wang XY, Ding ZB, Ke AW, Yang H, Wang L, Ai L, Cao Y, Zhou J, Fan J, Liu X, Gao Q. Shi JY, et al. Among authors: ke aw. Gut. 2021 May;70(5):951-961. doi: 10.1136/gutjnl-2020-320930. Epub 2020 Sep 30. Gut. 2021. PMID: 32998878

6

Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.

Zhang PF, Gao C, Huang XY, Lu JC, Guo XJ, Shi GM, Cai JB, Ke AW. Zhang PF, et al. Among authors: ke aw. Mol Cancer. 2020 Jun 27;19(1):110. doi: 10.1186/s12943-020-01222-5. Mol Cancer. 2020. PMID: 32593303 Free PMC article.

7

WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas.

Han WY, Wang J, Zhao J, Zheng YM, Chai XQ, Gao C, Cai JB, Ke AW, Fan J, Gao PT, Sun HX. Han WY, et al. Among authors: ke aw. Cancer Lett. 2023 Aug 1;568:216259. doi: 10.1016/j.canlet.2023.216259. Epub 2023 Jun 4. Cancer Lett. 2023. PMID: 37279851

8

Inhibition of autophagy in macrophage promotes IL-1β-mediated hepatocellular carcinoma progression via inflammasome accumulation and self-recruitment.

Gao Z, Feng SR, Chen JF, Li XG, Shi YH, Tang Z, Liu WR, Zhang X, Huang A, Luo XM, Zeng HY, Gao Q, Shi GM, Ke AW, Zhou J, Fan J, Fu XT, Ding ZB. Gao Z, et al. Among authors: ke aw. Biomed Pharmacother. 2023 May;161:114560. doi: 10.1016/j.biopha.2023.114560. Epub 2023 Mar 20. Biomed Pharmacother. 2023. PMID: 36940618 Free article.

9

Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy.

Dong ZR, Cai JB, Shi GM, Yang YF, Huang XY, Zhang C, Dong RZ, Wei CY, Li T, Ke AW, Fan J. Dong ZR, et al. Among authors: ke aw. Cancer Lett. 2023 Jun 28;564:216186. doi: 10.1016/j.canlet.2023.216186. Epub 2023 Apr 25. Cancer Lett. 2023. PMID: 37105392

10

Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis.

Guo XJ, Huang XY, Yang X, Lu JC, Wei CY, Gao C, Pei YZ, Chen Y, Sun QM, Cai JB, Zhou J, Fan J, Ke AW, Shi YG, Shen YH, Zhang PF, Shi GM, Yang GH. Guo XJ, et al. Among authors: ke aw. Cell Death Dis. 2023 Feb 2;14(2):79. doi: 10.1038/s41419-022-05406-3. Cell Death Dis. 2023. PMID: 36732324 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

78 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year